Our research focuses on how the cytoskeleton of cancer cells regulates transcriptional rewiring during tumour growth and dissemination. We aim to understand how such rewiring affects the tumour microenvironment.
WNT11-FZD7-DAAM1 signalling supports tumour initiating abilities and melanoma amoeboid invasion. Nat Commun (2020) 11(1):5315. PMID: 33082334
Myosin II reactivation and Cytoskeletal remodelling as a hallmark and a vulnerability in melanoma resistance. Cancer Cell (2020) 37(1):85-103. PMID: 31935375
Regional activation of Myosin II in cancer cells drives tumour progression via a secretory cross-talk with the immune microenvironment. Cell (2019) 176(4):757-774. PMID: 30712866
Reactivation of p53 by a cytoskeletal sensor to control the balance between DNA damage and tumour dissemination. J Natl Cancer Inst (2016) 108(1). PMID: 26464464
TGFb-induced transcription sustains amoeboid melanoma migration and dissemination. Curr Biol (2015) 16;25(22):2899-914. PMID: 26526369
Rho GTPases are molecular switches that control the cytoskeleton. Deregulation of Rho GTPases can result in aberrant function and disease, including cancer. The spreading of cancer cells from one part of the body to another, called metastasis, is one of the biggest causes of cancer death. The other major challenge in the clinic is drug resistance. In our lab we are studying how Rho GTPase signalling and cytoskeletal remodelling can control many processes: invasion and metastasis, tumour promoting inflammation and drug responses. We are particularly interested in understanding how cancer cells sense extracellular signals via their cytoskeleton and integrate the responses altering transcription. On the other hand, how cancer cells interact with the tumour microenvironment is crucial for tumour progression and dissemination. We aim to understand how this communication is controlled by the cytoskeleton of cancer cells.
The lab combines 'OMICs', molecular biology, microscopy in 3D matrices, co-culture systems, animal models and digital pathology in patient tissues to identify molecular determinants driven by Rho GTPase signalling that drive cancer progression and metastatic potential. Our ultimate goal is to define if manipulations in the cytoskeleton of cancer cells will lead to improved efficacy of current therapeutic approaches.
Podoplanin drives dedifferentiation and amoeboid invasion of melanoma. de Winde CM, George SL, Crosas-Molist E et al. iScience (2021) 24(2) 102976
RhoGTPase Signalling in Cancer Progression and Dissemination. Crosas-Molist E, Samain R, Kohlhammer L et al. Physiol Rev (2021) (2)
A preclinical pipeline to evaluate migrastatics as therapeutic agents in metastatic melanoma Maiques O, Fanshawe B, Crosas-Molist E et al. British Journal of Cancer (2021) 125(7) 699-713
Kallikrein-related peptidase 6 is associated with the tumour microenvironment of pancreatic ductal adenocarcinoma Candido JB, Maiques O, Boxberg M et al. Cancers (2021) 13(7)
Location, location, location: Melanoma cells "living at the edge". Maiques O, Sanz-Moreno V Exp Dermatol (2021) (2)
WNT11-FZD7-DAAM1 signalling supports tumour initiating abilities and melanoma amoeboid invasion Rodriguez-Hernandez I, Maiques O, Kohlhammer L et al. Nature Communications (2020) 11(7)
First-in-Human Study of AT13148, a Dual ROCK-AKT Inhibitor in Patients with Solid Tumors McLeod R, Kumar R, Papadatos-Pastos D et al. Clinical Cancer Research (2020) 26(7) 4777-4784
CDC42EP5/BORG3 modulates SEPT9 to promote actomyosin function, migration, and invasion Farrugia AJ, Rodríguez J, Orgaz JL et al. Journal of Cell Biology (2020) 219(7)
Cancer Burden Is Controlled by Mural Cell-β3-Integrin Regulated Crosstalk with Tumor Cells Wong PP, Muñoz-Félix JM, Hijazi M et al. Cell (2020) 181(7) 1346-1363.e21
What does not kill you makes you stronger: surviving anti-cancer therapies by cytoskeletal remodeling and Myosin II reactivation Orgaz JL, Sanz-Moreno V Molecular and Cellular Oncology (2020) 7(7)For additional publications, please click here
I received my first degree in chemistry and later a masters degree in biochemistry from the University of Oviedo in Spain, followed by a PhD in chemical sciences at the University of Cantabria. After a short postdoc in the same lab with a Lady Tata Memorial Trust Fellowship, I moved to the Institute of Cancer Research in London as a CRUK and Marie Curie Intra-european Fellow with Chris Marshall. In 2008, I received an EACR 40th Anniversary Research Award. In 2011 I established my lab with a CRUK Career Development Fellowship at King’s College London (Randall Centre for cell and molecular biophysics). In 2015, I was highly commended as CRUK Communications and Brand Ambassador for communicating science to the public. In 2017 I was awarded the BSCB Women in Cell Biology Early Career Award Medal. The same year I received a CRUK Senior Fellowship and I was badged CRUK Werth Trust Fellow. I joined Barts Cancer Institute as a Professor of Cancer Cell Biology in 2018.